See what’s new.
restor3d Secures $38 Million in Growth Capital to Drive Expansion and Innovation in Personalized Orthopedic Solutions
Newly raised funds will allow the Duke spinout to scale its personalized orthopedic solutions, advancing 3D printing and AI technologies for improved surgical outcomes.
Uplinza® (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease
Originally developed at Duke, Amgen’s UPLIZNA® secures FDA approval as the first treatment for IgG4-related disease, achieving an 87% reduction in flare risk through CD19+ B-cell targeting.
Isolere Bio by Donaldson Passes Most Significant Milestone To-Date, Announces Availability of Manufacturing-Grade IsoTag™ AAV Reagent
Isolere Bio by Donaldson, a Duke spinout, announces the launch of its manufacturing-grade IsoTag™ AAV reagent, marking a major milestone in advancing gene therapy manufacturing technologies.
Gene therapy developed at Duke to be commercialized by a local biotechnology company
A universal gene editing therapy for Pompe disease, invented in the lab of Duke Professor Dwight Koeberl, is licensed for further development by local start-up GeneVentiv.
GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
GeneVentiv Therapeutics, a Raleigh-based gene therapy company, has taken an exclusive license to Pompe disease gene editing technology developed in the lab of Professor Dwight Koeberl (Pediatrics, SOM).
Fellow Turned Inventor Gives Glaucoma Care an Upgrade
While Gabriel and Challa iterated on the new and improved GDD, they also tapped into Duke’s innovation ecosystem resources and connected with Duke’s Office for Translation & Commercialization (OTC), Duke’s tech transfer office.
10 Years, 60 Startups, $105 Million – and Counting: Duke Capital Partners Leads the Way in Alumni Investing
From its start as one of the first alumni-led venture groups of its kind, Duke Capital Partners continues to connect Duke alumni investors with innovative Duke-affiliated startups – and train the next generation of venture…
Breath of Life: Duke Inventors Secure $5M for Novel Oxygenation Startup
Duke clinician partners with Duke engineers to tackle an elusive critical care challenge: Can oxygen be delivered directly into the bloodstream through a catheter?
VQ Biomedical secures $5M, including a seed round led by Harbright, WIN, and DCP
VQ Biomedical is a Duke University start-up and DCP portfolio company resulting from the collaboration Duke clinicians and engineers.